FDA panel discusses Merck's Vorapaxar

|About: Merck & Co Inc. (MRK)|By:, SA News Editor

A panel of external FDA advisers is meeting to discuss whether to approve recommending Merck's (MRK -0.8%) Vorapaxar drug for preventing drug clots.

On Monday, the agency said in a preliminary review that the treatment should be authorized following "robustly positive" clinical trial results.

Vorapaxar, which Merck plans to sell under the brand name Zontivity, is designed to prevent heart-related deaths, heart attacks and strokes in patients who have recently suffered a heart attack but not a stroke.

You can follow updates from the meeting on Twitter here.